MY192577A - Ophthalmic solution comprising epinastine - Google Patents

Ophthalmic solution comprising epinastine

Info

Publication number
MY192577A
MY192577A MYPI2019002321A MYPI2019002321A MY192577A MY 192577 A MY192577 A MY 192577A MY PI2019002321 A MYPI2019002321 A MY PI2019002321A MY PI2019002321 A MYPI2019002321 A MY PI2019002321A MY 192577 A MY192577 A MY 192577A
Authority
MY
Malaysia
Prior art keywords
ophthalmic solution
epinastine
ingredients
salt
substantially free
Prior art date
Application number
MYPI2019002321A
Other languages
English (en)
Inventor
Masahiro Kawahata
Naoki Matsumoto
Hiroyuki Inoue
Tomoki Hara
Sachie Hikage
Takashi Morimoto
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY192577A publication Critical patent/MY192577A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019002321A 2016-10-28 2017-10-27 Ophthalmic solution comprising epinastine MY192577A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016211535A JP6134853B1 (ja) 2016-10-28 2016-10-28 エピナスチン含有点眼液
PCT/JP2017/038948 WO2018079721A1 (ja) 2016-10-28 2017-10-27 エピナスチン含有点眼液

Publications (1)

Publication Number Publication Date
MY192577A true MY192577A (en) 2022-08-29

Family

ID=58745757

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019002321A MY192577A (en) 2016-10-28 2017-10-27 Ophthalmic solution comprising epinastine

Country Status (7)

Country Link
JP (1) JP6134853B1 (ko)
KR (3) KR102659499B1 (ko)
AU (1) AU2017348597A1 (ko)
MY (1) MY192577A (ko)
PH (1) PH12019500934A1 (ko)
TW (1) TWI750248B (ko)
WO (1) WO2018079721A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
JP7355539B2 (ja) * 2018-07-20 2023-10-03 ロート製薬株式会社 眼科組成物
JP7458159B2 (ja) * 2018-09-28 2024-03-29 ロート製薬株式会社 眼科組成物
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
KR20110104367A (ko) * 2010-03-16 2011-09-22 삼천당제약주식회사 무보존제 안과용 조성물
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
JPWO2015125921A1 (ja) * 2014-02-20 2017-03-30 わかもと製薬株式会社 保存効力を有する医薬用水性組成物

Also Published As

Publication number Publication date
JP2018070500A (ja) 2018-05-10
TW201821060A (zh) 2018-06-16
WO2018079721A1 (ja) 2018-05-03
TWI750248B (zh) 2021-12-21
KR20190075956A (ko) 2019-07-01
KR20230014870A (ko) 2023-01-30
AU2017348597A1 (en) 2019-05-16
KR20240054409A (ko) 2024-04-25
KR102659499B1 (ko) 2024-04-19
JP6134853B1 (ja) 2017-05-24
KR102491425B1 (ko) 2023-01-20
PH12019500934A1 (en) 2019-12-02

Similar Documents

Publication Publication Date Title
MY192577A (en) Ophthalmic solution comprising epinastine
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
MA39727A (fr) Compositions antimicrobiennes pour végétaux
SG10201811454WA (en) Materials and methods for controlling infections
MY182507A (en) Aqueous ophthalmic solution
WO2018211454A3 (en) CRYOPROTECTRICE AND / OR CRYOCONSERVATOR COMPOSITION, METHODS AND USES THEREOF
MY187945A (en) Improved mouthwash preparation
MY192532A (en) Liquid pharmaceutical composition
MX2017016096A (es) Agente antihipertensivo.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MY183391A (en) Refrigerant pack
AR101581A1 (es) Composición de colutorio
EP3468366A4 (en) SAFE HERBICIDE COMPOSITIONS WITH HALAUXIFEN AND METHOD FOR USE THEREOF IN COALS
NZ733329A (en) Microbiocidal control in the processing of poultry
MY198474A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HUE053827T2 (hu) Tárolás során stabil mikrobicid koncentrátumok és alkalmazásuk tartósítószerként
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
GB2553870B (en) Sweat-inhibiting and/or deodorizing cosmetic agents with low emulsifier content
PH12016501448A1 (en) Antifungal composition
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease